SCHEMBL5151601

SCHEMBL5151601

CCCOc1ccccc1-c1ccccc1C(C)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
MAPT P10636 5/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NR1I2 O75469 1/20 0.48
CHRM2 P08172 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADRA2A P08913 1/20 0.48
OPRK1 P41145 1/20 0.48
HTR2B P41595 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HIF1A Q16665 1/20 0.47
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
ADRB3 P13945 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10751518 0.87 PTPN11 (0.56) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL3135517 0.86 LMNA (0.74) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL9702602 0.86 PTPN11 (0.49) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
Lithium SCHEMBL385607 0.85 LMNA (0.72) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL385606 0.85 LMNA (0.72) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL10438816 0.82 HTR7 (0.53) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL10750541 0.79 PTPN11 (0.64) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL27914187 0.79 PTGER1 (0.66) SMN1; SMN2MAPTL3MBTL1MEN1KMT2A
SCHEMBL7649963 0.79 LMNA (0.54) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL9702630 0.79 LMNA (0.54) LMNASMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R LMNA 3198/4885SMN1; SMN2 3867/4885ALDH1A1 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.